<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02993575</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF-16.08</org_study_id>
    <nct_id>NCT02993575</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients</brief_title>
  <acronym>FANATIC</acronym>
  <official_title>Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion as Therapy to Patients With an Infection in the Intensive Care Unit (ICU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tergooi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gelderse Vallei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared&#xD;
      to non-ICU patients. The investigators will determine total and free flucloxacillin&#xD;
      concentrations in 30 ICU patients, who will get continuous (n=10) or intermittent infusion&#xD;
      (n=20) of flucloxacillin as standard care.&#xD;
&#xD;
      Full pharmacokinetic curves will be taken for individual patients on the intermittent dosing&#xD;
      regimen and limited sampling will be taken for individual patients on the continuous dosing&#xD;
      regimen on day 2 and 4.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared&#xD;
      to non-ICU patients. There is a substantial risk that present standard dosing regimens of&#xD;
      antibiotics lead to suboptimal outcomes for patients on the ICU. To prevent the risk of&#xD;
      inadequate dosing in critically ill patients, it is important to optimize dosing regimens in&#xD;
      ICU patients.&#xD;
&#xD;
      With this study the investigators will define pharmacokinetics of flucloxacillin in ICU&#xD;
      patients and search for variables influencing pharmacokinetics. By using population modeling&#xD;
      the investigators will simulate different dosing regimens, intermittent and continuous, and&#xD;
      compare probability of target attainment between continuous and intermittent infusion.&#xD;
&#xD;
      To be able to include 30 patients within the study duration, a multi-centre approach is&#xD;
      necessary.&#xD;
&#xD;
      Patients will receive standard care, as stated in the product characteristics or according to&#xD;
      local protocols. Minimally invasive blood sampling for pharmacokinetic analysis will be&#xD;
      retrieved through a central venous catheter or an arterial line. Full pharmacokinetic curves&#xD;
      will be taken for individual patients on the intermittent dosing regimen and limited sampling&#xD;
      will be taken for individual patients on the continuous dosing regimen on day 2 and 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">April 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance</measure>
    <time_frame>Day 2 and 4</time_frame>
    <description>Full pharmacokinetic curves will be taken on Day 2 and Day 4</description>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Bacterial Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucloxacillin</intervention_name>
    <description>Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion</description>
    <other_name>Floxapen</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples for determination of total flucloxacillin and free flucloxacillin&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving flucloxacillin for treating a suspected or proven bacterial&#xD;
        infection at the ICU will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is admitted to an ICU&#xD;
&#xD;
          2. Subject is at least 18 years old on the day of the first dosing&#xD;
&#xD;
          3. Is managed with a central venous catheter or arterial line&#xD;
&#xD;
          4. Patient is treated with flucloxacillin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Has previously participated in this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Flucloxacillin</keyword>
  <keyword>Continuous infusion</keyword>
  <keyword>Intensive Care Unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Floxacillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

